Current Allergy and Asthma Reports

, 6:247

New targets for modifying mast cell activation in asthma

Article

DOI: 10.1007/s11882-006-0042-3

Cite this article as:
Ennis, M. Curr Allergy Asthma Rep (2006) 6: 247. doi:10.1007/s11882-006-0042-3

Abstract

Mast cells play a central role in innate immunity and in orchestrating the asthmatic response. Current medication relies on β-agonists to relieve bronchoconstriction and steroids to reduce inflammation. However, recently drugs such as leukotriene-receptor antagonists and anti-immunoglobulin E have come on to the market. In this paper, a number of potential targets for modifying mast cell activation in asthma are reviewed. Some are already under study, including clinical trials (eg, tryptase inhibitors); others are more speculative (eg, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity). In each case, where data are available, the action of the agents on human lung mast cells is described.

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Respiratory Research Group, School of Medicine and DentistryThe Queen’s University of Belfast, Institute of Clinical ScienceBelfastUK